Reduced thiopurine methyltransferase activity and development of side effects of azathioprine treatment in patients with rheumatoid arthritis

Arthritis and Rheumatism

Volumn 41, Issue 10, 1998, Pages 1858-1866

  Stolk, Jan N ^a   Boerbooms, Agnes M T ^a   De Abreu, Ronney A ^a   De Koning, Diana G M ^a   Van Beusekom, Henk J ^b   Muller, Wim Hissink ^b   Van De Putte, Leo B A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b St Elisabeth Hospital   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; AZATHIOPRINE; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; PURINE NUCLEOSIDE PHOSPHORYLASE; THIOPURINE METHYLTRANSFERASE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SAFETY; ENZYME ACTIVITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; STATISTICAL ANALYSIS; TREATMENT PLANNING;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTHRITIS, RHEUMATOID; AZATHIOPRINE; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; LONGITUDINAL STUDIES; MALE; METHYLTRANSFERASES; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 0031715622     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199810)41:10<1858::AID-ART19>3.0.CO;2-8     Document Type: Article

References (40)

1. Zimm S, Johnson GE, Chabner BA, Poplack DG. Cellular pharmacokinetics of mercaptopurine in human neoplastic cells and cell lines. Cancer Res 1985;45:4156-61.
2. Tidd DM, Paterson AR. A biochemical mechanism for the delayed cytotoxic reaction of 6-mercaptopurine. Cancer Res 1974;34:738-46.
3. Elion GB. The purine path to chemotherapy. Science 1989;24: 441-7.
4. Harris J, Jessop JD, Chaput de Saintonge DM. Further experience with azathioprine in rheumatoid arthritis. BMJ 1971;4:463-4.
5. Hunter T, Urowitz MB, Gordon DA, Smythe HA, Ogryzlo MA. Azathioprine in rheumatoid arthritis: a long-term follow-up study. Arthritis Rheum 1975;18:15-20.
6. Hamdy H, McKendry RJR, Mierins E, Liver JA. Low-dose methotrexate compared with azathioprine in the treatment of rheumatoid arthritis: a twenty-four-week controlled clinical trial. Arthritis Rheum 1987;30:361-8.
7. Whisnant JK, Pelkey J. Rheumatoid arthritis: treatment with azathioprine (IMURAN®): clinical side-effects and laboratory abnormalities. Ann Rheum Dis 1982;41 Suppl 1:44-7.
8. Bunch TW, O'Duffy JD. Disease-modifying drugs for progressive rheumatoid arthritis. Mayo Clin Proc 1980;55:161-79.
9. Old CW, Flannery EP, Grogan TM, Stone WH, San Antonio RP. Azathioprine-induced pure red blood cell aplasia. JAMA 1978; 240:552-4.
10. Jeurissen MEC, Boerbooms AMT, van de Putte LBA. Pancytopenia related to azathioprine in rheumatoid arthritis. Ann Rheum Dis 1988;47:503-5.
11. Jeurissen MEC, Boerbooms AMT, van de Putte LBA, Kruijsen MW. Azathioprine induced fever, chills, rash, and hepatotoxicity in rheumatoid arthritis. Ann Rheum Dis 1990;49:25-7.
12. Knowles SR, Gupta AK, Shear NH, Sauder D. Azathioprine hypersensitivity-like reactions - a case report and a review of the literature. Clin Exp Dermatol 1995;20:353-6.
13. Kelley WN, Rosenbloom FM, Seegmiller JE. The effects of azathioprine (Imuran) on purine synthesis in clinical disorders of purine metabolism. J Clin Invest 1967;46:1518-29.
14. Lennard L, van Loon JA, Lilleyman JS, Weinshilboum RM. Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin Pharmacol Ther 1987;41:18-25.
15. Chocair PR, Duley JA, Simmonds HA, Cameron JS. The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients. Transplantation 1992;53: 1051-6.
16. Kerstens PJSM, Stolk JN, Hilbrands LB, van de Putte LBA, De Abreu RA, Boerbooms AMT. 5′-nucleotidase and azathioprine-related bone-marrow toxicity [letter]. Lancet 1993;342:1245-6.
17. Stolk JN, Boerbooms AMT, De Abreu RA, Kerstens PJSM, de Koning DGM, de Graaf R, et al. Purine enzyme activities in recent onset rheumatoid arthritis: are there differences between patients and healthy controls? Ann Rheum Dis 1996;55:733-8.
18. Kerstens PJ, Stolk JN, Boerbooms AM, Lambooy LH, de Graaf R, De Abreu RA, et al. Purine enzymes in rheumatoid arthritis: possible association with response to azathioprine: a pilot study. Ann Rheum Dis 1994;53:608-11.
19. Koren G, Langevin AM, Olivieri N, Giesbrecht E, Zipursky A, Greenberg M. Diurnal variation in the pharmacokinetics and myelotoxicity of mercaptopurine in children with acute lymphocytic leukemia. Am J Dis Child 1990;144:1135-7.
20. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
21. Jeurissen MEC, Boerbooms AMT, van de Putte LBA, Doesburg WH, Mulder J, Rasker JJ, et al. Methotrexate versus azathioprine in the treatment of rheumatoid arthritis: a forty-eight-week randomized, double-blind trial. Arthritis Rheum 1991;34:961-72.
22. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992;35:498-502.
23. Ritchie DM, Boyle JA, McInnes JM, Jasani MK, Dalakos TG, Grieveson P, et al. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. QJM 1968;37:397-406.
24. Van der Heijde DM, van 't Hof MA, van Riel PL, Theunisse HA, Lubberts EW, van de Putte LBA. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990;49:916-20.
25. Stolk JN, De Abreu RA, Boerbooms AMT, de Koning DGM, de Graaf R, Kerstens PJSM, et al. Purine enzyme activities in peripheral blood mononuclear cells: comparison of a new non-radiochemical high-performance liquid chromatography procedure and a radiochemical thin-layer chromatography procedure. J Chromatogr B Biomed Sci Appl 1995;666:33-43.
26. Weinshilboum RM, Raymond FA, Pazmino PA. Human erythrocyte thiopurine methyltransferase: radiochemical micro assay and biochemical properties. Clin Chim Acta 1978;85:323-33.
27. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenetic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980;32:651-62.
28. Elion GB, Hitchings GH. Azathioprine. In: Sartorelli AC, Johns DG, editors. Handbook of experimental pharmacology: new series. Berlin: Springer Verlag; 1975. p. 404-25.
29. Leipold G, Schütz E, Haas JP, Oellerich M. Azathioprine-induced severe pancytopenia due to a homozygous two-point mutation of the thiopurine methyltransferase gene in a patient with juvenile HLA-B27-associated spondylarthritis. Arthritis Rheum 1997;40: 1896-8.
30. Lennard L, Lilleyman JS, van Loon J, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukemia. Lancet 1990;336:225-9.
31. Krynetski EY, Tai HL, Yates CR, Fessing MY, Loennechen T, Schuetz JD, et al. Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics 1996;6:279-90.
32. Woodland J, Chaput de Saintonge DM, Evans SJW, Sharman VL, Currey HLF. Azathioprine in rheumatoid arthritis: double blind study of full versus half doses versus placebo. Ann Rheum Dis 1981;40:355-9.
33. Huskisson EC. Azathioprine. Clin Rheum Dis 1984;10:325-32.
34. Schutz E, Gummert J, Mohr F, Oellerich M. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient [letter]. Lancet 1993;341:436.
35. Soria-Royer C, Legendre C, Mircheva J, Premel S, Beaune P, Kreis H. Thiopurine-methyl-transferase activity to assess azathioprine myelotoxicity in renal transplant recipients [letter]. Lancet 1993;341:1593-4.
36. Lennard L, van Loon J, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989;46:149-54.
37. Lennard L, Lilleyman JS. Are children with lymphoblastic leukemia given enough 6-mercaptopurine? Lancet 1987;2:785-7.
38. Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai HL, Pui CH, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997;126:608-14.
39. Ohlman S, Lafolie P, Lindholm A, Liliemark J, Tyden G, Peterson C. Large interindividual variability in bioavailability of azathioprine in renal transplant recipients. Clin Transplant 1993;7:65-70.
40. Lennard L, Keen D, Lilleyman JS. Oral 6-mercaptopurine in childhood leukemia: parent drug pharmacokinetics and active metabolite concentrations. Clin Pharmacol Ther 1986;40:287-92.